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Business Potential
• New market entry from microbial library screening
(industrial biotechnology) to mammalian library
screening (pharmaceutical industry)
• High throughput compatible matrix-based 3D cell
culture technology
• Primary cell line development
o Patient-derived cancer (stem) cell lines
• Phenotypic high throughput screening
o Enrichment of cancer-derived cell subpopulations
for targeted therapy
o Discovery of novel biologics and efficacy and 
toxicology studies with small molecules
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Project goal
The screening of large cell libraries is an important process in
pharmaceutical discovery and R&D, e.g. to define drug targets or
develop effective medicines. The goal of this project is the
implementation of a screening platform based on 3D cultivation of
primary human mesothelioma cells encapsulated in alginate
hydrogels (Fig. 1) . To this end new hydrogel compositions will be
designed, tested and finally utilized in the Nanoliter Reactor
(NLR) cultivation system (Fig. 2) that enables high throughput
analysis of 3D cell cultures.
Key Findings
• Successful manual cell encapsulation of mesothelioma cell line
ZL55SPT into alginate beads (Fig. 1A)
• Life/dead staining of encapsulated ZL55SPT cells (Fig. 1B)
Scientific Innovation
• 3D cell culture of mammalian cells in Ca-alginate hydrogels 
offering different microenvironments:
o Blending of alginate with natural environment mimicking 
compounds 
o Modification of the hydrogel stiffness to adapt to native 
tissue 
• Implementation of the modified Ca-alginate hydrogel in the 
NLR-technology to produce reliable monodisperse capsules 
at high reproducibility.
• Development of a novel method to generate patient-derived 
primary mesothelioma cell lines in 3D (e.g. cell 
subpopulations, like cancer stem cells) from a biopsy in a 
high throughput manner using the NLR-technology. 
• Retain the encapsulated mesothelioma cells in their native 
state to use them for drug development/treatment to gain 
predictive drug responses. 
• Comparison of in vitro to in vivo and come up with 
strategies to develop personalized drug treatment regimes.
Fig. 1: Mesothelioma cell line ZL55SPT encapsulated in alginate beads. A) Cell
growth and spheroid formation after 9 days of incubation. B) Life/Dead staining
(green/red) of cells after 21 days of incubation.
Fig. 2: NLR technology scheme
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